Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DNI28K
|
|||
| Drug Name |
TP-0184
|
|||
| Synonyms |
Itacnosertib; UNII-22Z53X5LHF; 22Z53X5LHF; 1628870-27-8; methylpiperazin-1-yl)phenyl]pyrimidine-2,4-diamine; N4-([2,2'-bipyridin]-3-yl)-N2-[3-methoxy-4-(4-; 2-N-[3-methoxy-4-(4-methylpiperazin-1-yl)phenyl]-4-N-(2-pyridin-2-ylpyridin-3-yl)pyrimidine-2,4-diamine; Itacnosertib [INN]; SCHEMBL16129103; GTPL10632; TP0184; example 11 [WO2014151871A9]; 2,4-Pyrimidinediamine, N4-(2,2'-bipyridin)-3-yl-N2-(3-methoxy-4-(4-methyl-1-piperazinyl)phenyl)-; N2-(3-Methoxy-4-(4-methylpiperazin-1-yl)phenyl)-N4-(2-(pyridin-2-yl)pyridin-3-yl)pyrimidine-2,4-diamine
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199] | Phase 1 | [1] | |
| Company |
Sumitomo Dainippon Pharma
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C26H28N8O
|
|||
| Canonical SMILES |
CN1CCN(CC1)C2=C(C=C(C=C2)NC3=NC=CC(=N3)NC4=C(N=CC=C4)C5=CC=CC=N5)OC
|
|||
| InChI |
1S/C26H28N8O/c1-33-14-16-34(17-15-33)22-9-8-19(18-23(22)35-2)30-26-29-13-10-24(32-26)31-21-7-5-12-28-25(21)20-6-3-4-11-27-20/h3-13,18H,14-17H2,1-2H3,(H2,29,30,31,32)
|
|||
| InChIKey |
XSQKEVGTZSBVBR-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 1628870-27-8
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03429218) First-in-human Study of Oral TP-0184 in Patients With Advanced Solid Tumors. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Sumitomo Dainippon Pharma. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.